Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma

Drug Name (Brand / Generic)

Opdivo / Nivolumab

Developed by

Bristol-Myers Squibb (BMS)

Therapy Class

Human immunoglobulin G4 (IgG4) monoclonal antibody

Current Indication

Unresectable or Metastatic Melanoma

Market Sector

Oncology

Development Status

Approved in the US and Europe
Expand

Go Top